Loading...
Loading...
Jefferies maintained ONYX Pharmaceuticals
ONXX with a Buy rating and raised the price target from $96.00 to $104.00.
Jefferies analyst Biren Amin commented, "Based on recent events incl frontline data and NCCN Compendium listing, and Pomalyst launch, we conducted a follow-up survey in myeloma, and observed 1st/2nd line Kyprolis use could be significantly higher than consensus. We raise our Kyprolis sales projections with a new $104 PT (v $96 previously)."
ONYX Pharmaceuticals closed at $86.61 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in